SHR-1139 Injection

DRUG4 trials

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd, Atridia Pty Ltd., Shandong First Medical University

Conditions

Moderate to Severe Plaque PsoriasisPsoriasisPyoderma Gangrenosum

Phase 1

A Trial of SHR-1139 in Healthy Volunteers

Active, not recruitingNCT07078695

Atridia Pty Ltd.Psoriasis

Start: 2025-08-19End: 2026-09-30Target: 24Updated: 2026-03-19

Phase 2

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

Active, not recruitingNCT06875934

Guangdong Hengrui Pharmaceutical Co., LtdModerate to Severe Plaque Psoriasis

Start: 2025-03-28End: 2026-10-31Updated: 2025-07-14

A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum

RecruitingNCT07337564

Shandong First Medical UniversityPyoderma Gangrenosum

Start: 2026-01-29End: 2028-06-01Target: 10Updated: 2026-09-09

A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum

Not yet recruitingNCT07444684

Guangdong Hengrui Pharmaceutical Co., LtdPyoderma Gangrenosum

Start: 2026-03-05End: 2028-04-01Target: 20Updated: 2026-03-03